COMMUNIQUÉS West-GlobeNewswire

IBA reports solid Full Year 2024 results
20/03/2025
Read the entire full year 2024 results press release here Louvain-la-Neuve, Belgium, 20 March 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its consolidated [...]
IBA publie des résultats solides pour l'année 2024
20/03/2025
Cliquez ici pour lire l'intégralité du communiqué de presse des résultats de l'exercice 2024 Louvain-La-Neuve, Belgique, jeudi 20 mars 2025 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’ [...]
Press release: Sequana Medical to Sponsor Liver Connect, 5th Annual Conference of Chronic Liver Disease Foundation
20/03/2025
Sequana Medical to Sponsor Liver Connect, 5 th Annual Conference of Chronic Liver Disease Foundation Ghent, Belgium – 20 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical") , a [...]
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20/03/2025
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition [...]
Communiqué de presse : Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie
20/03/2025
Sanofi va acquérir l’anticorps bispécifique de Dren Bio – un « engageur » des cellules myéloïdes pour la déplétion profonde des lymphocytes B –, et étoffe son portefeuille en immunologie L’agent de déplétion profonde [...]
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
20/03/2025
Met 2024 growth targets for product sales (+13% vs 2023) and total revenues (+10% vs 2023) Strong year-end cash position of €168.3 million including sale of Priority Review Voucher 1 , successful private placement and [...]
Valneva publie ses résultats financiers 2024 et fait un point sur son activité et ses perspectives financières
20/03/2025
Atteinte des objectifs 2024 de croissance des ventes (+13% vs 2023) et de chiffre d’affaires (+10% vs 2023) Solide position de trésorerie de 168,3 millions d’euros à fin 2024 incluant les produits de la vente du bon de [...]
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
20/03/2025
CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today [...]
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
20/03/2025
YARDLEY, Pa., March 19, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the cancellation of [...]
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
20/03/2025
Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10 ‑ million ‑ patient market Acquisition advances Paratek’s vision to become a [...]
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
20/03/2025
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO ® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of [...]
COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents
20/03/2025
TORONTO, ONTARIO, March 19, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“ COSCIENS ” or the “ Company ”), a life science company which develops and commercializes a diversified portfolio [...]
Hyku Biosciences Appoints Keith Wilcoxen, PhD, as Chief Scientific Officer
19/03/2025
BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Hyku Biosciences, a pioneer in precision medicine, today announced the appointment of Keith Wilcoxen, PhD, as Chief Scientific Officer. Dr. Wilcoxen has more than 25 [...]
Pacific Health Care Organization, Inc. Reports its 2024 Year-End Financial Results
19/03/2025
Irvine, CA, March 19, 2025 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) today filed with the Securities and Exchange Commission (the “Commission”) its annual report on Form [...]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
19/03/2025
NOVATO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare [...]
Galecto Reports Full-Year 2024 Financial Results
19/03/2025
Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge [...]
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
19/03/2025
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene [...]
Basel Medical Group Ltd Announces Exercise of Overallotment Option
19/03/2025
Singapore, March 19, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and [...]
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
19/03/2025
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product [...]

Pages